These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Factor Xa inhibitors: critical considerations for clinical development and testing. Becker RC J Thromb Thrombolysis; 2021 Aug; 52(2):397-402. PubMed ID: 33991266 [TBL] [Abstract][Full Text] [Related]
4. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. Nafee T; Aslam A; Chi G; Pahlavani S; Nimri D; Kuchkuntla AR; Talib U; Michalak N; Daaboul Y; Korjian S; Gallo A; Gibson CM Expert Rev Cardiovasc Ther; 2017 Apr; 15(4):237-245. PubMed ID: 28282497 [TBL] [Abstract][Full Text] [Related]
5. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Ghadimi K; Dombrowski KE; Levy JH; Welsby IJ Expert Rev Hematol; 2016; 9(2):115-22. PubMed ID: 26686866 [TBL] [Abstract][Full Text] [Related]
6. Antidote reverses anticoagulant effects of factor Xa inhibitors in minutes, studies show. Mayor S BMJ; 2015 Nov; 351():h6086. PubMed ID: 26567177 [No Abstract] [Full Text] [Related]
7. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317 [TBL] [Abstract][Full Text] [Related]
8. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. Ansell JE J Thromb Thrombolysis; 2016 Feb; 41(2):248-52. PubMed ID: 26449414 [TBL] [Abstract][Full Text] [Related]
9. Anticoagulation therapy: Reversal of factor Xa activity. Huynh K Nat Rev Cardiol; 2016 Nov; 13(11):636. PubMed ID: 27629510 [No Abstract] [Full Text] [Related]
11. The DaXa-inhibition assay: A concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs. van Pelt LJ; Lukens MV; Testa S; Chatelain B; Douxfils J; Mullier F Thromb Res; 2018 Aug; 168():63-66. PubMed ID: 29909093 [No Abstract] [Full Text] [Related]
12. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221 [TBL] [Abstract][Full Text] [Related]
13. Factor Xa--a promising target for drug development. Kaiser B Cell Mol Life Sci; 2002 Feb; 59(2):189-92. PubMed ID: 11915937 [No Abstract] [Full Text] [Related]
14. Reversal of anticoagulants: an overview of current developments. Greinacher A; Thiele T; Selleng K Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors. Huang C; Wang W; Li Y; Zhang S; Meng F; Xu W; Yuan J; Chen L Oncotarget; 2017 Jun; 8(23):37186-37199. PubMed ID: 28415603 [TBL] [Abstract][Full Text] [Related]
19. Dabigatran: ready for prime time? Karthikeyan G; Eikelboom JW; Hirsh J Pol Arch Med Wewn; 2010 Apr; 120(4):137-42. PubMed ID: 20424539 [TBL] [Abstract][Full Text] [Related]
20. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy. Sartori M; Cosmi B J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]